Trubion was a publicly held biopharmaceutical

Biopharmaceutical

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins , nucleic acids and living microorganisms like virus and bacteria where the virulence of viruses and bacteria is reduced by the process of attenuation, they can be used for therapeutic or in vivo diagnostic...

 company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune

Autoimmune disease

Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the body actually attacks its own cells. The immune system mistakes some part of the body as a pathogen and attacks it. This may be restricted to...

 and inflammatory diseases and cancer

Cancer

Cancer , known medically as a malignant neoplasm, is a large group of different diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade nearby parts of the body. The cancer may also spread to more distant parts of the...

. Trubion was acquired by Emergent BioSolutions

Emergent BioSolutions

Emergent BioSolutions is a multinational biopharmaceutical company headquartered in Rockville, Maryland. Emergent develops vaccines and therapeutics targeting infectious diseases, oncology and autoimmune disorders. Founded as BioPort Corporation in 1998, the company was named Emergent...

 on October 28, 2010. Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.

In December 2005, Trubion entered into a collaborative agreement with Wyeth

Wyeth

Wyeth, formerly one of the companies owned by American Home Products Corporation , was a pharmaceutical company. The company was based in Madison, New Jersey, USA...

 for the development and worldwide commercialization of CD20

CD20

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity....

-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion’s contract with Wyeth extended through December 22, 2009.

Former product pipeline

Name	Platform	Indication	Status	Collaboration	Research
TRU-015	SMIP	Rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks synovial joints. The process produces an inflammatory response of the synovium secondary to hyperplasia of synovial cells, excess synovial fluid, and the development...	Phase 2b	Wyeth	Phase 2b initiation EULAR data
SBI-087	SMIP	Rheumatoid arthritis	Phase 1	Wyeth	Recent data
SBI-087	SMIP	Systemic lupus erythematosus Systemic lupus erythematosus Systemic lupus erythematosus , often abbreviated to SLE or lupus, is a systemic autoimmune disease that can affect any part of the body. As occurs in other autoimmune diseases, the immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage...	Phase 1	Wyeth
TRU-016	SMIP	Chronic lymphocytic leukemia Chronic lymphocytic leukemia B-cell chronic lymphocytic leukemia , also known as chronic lymphoid leukemia , is the most common type of leukemia. Leukemias are cancers of the white blood cells . CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by...	Phase 1/2	Trubion Proprietary Technology	ASCO 2008 Poster Presentation
TRU-016	SMIP	Non-Hodgkin lymphoma Non-Hodgkin lymphoma The non-Hodgkin lymphomas are a diverse group of blood cancers that include any kind of lymphoma except Hodgkin's lymphomas. Types of NHL vary significantly in their severity, from indolent to very aggressive....	Pre-clinical	Trubion Proprietary Technology
TRU-016	SMIP	Autoimmune disease Autoimmune disease Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the body actually attacks its own cells. The immune system mistakes some part of the body as a pathogen and attacks it. This may be restricted to...  and inflammation	Pre-clinical	Trubion Proprietary Technology

Former technology

Trubion’s product development efforts were focused on three technology pillars: SMIP protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals.

SMIP, or small modular immunopharmaceutical

Small modular immunopharmaceutical

Small modular immunopharmaceuticals, or SMIPs for short, are artificial proteins that are intended for use as pharmaceutical drugs. They are largely built from parts of antibodies , and like them have a binding site for antigens that could be used for monoclonal antibody therapy...

, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity as mAbs.

SCORPION protein therapeutics are also single chain polypeptides composed of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.

TRU-ADhanCe potency enhancing technology was designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, or ADCC

ADCC

ADCC may refer to:* ADCC Submission Wrestling Championship*Antibody-dependent cellular cytotoxicity*Air Defence Cadet Corps*Viking ADCC Viking Line cruiseferry...

. TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in vivo

In vivo

In vivo is experimentation using a whole, living organism as opposed to a partial or dead organism, or an in vitro controlled environment. Animal testing and clinical trials are two forms of in vivo research...

half lives.